Skip to main content

Table 5 Comparison of treatment outcome between groups 1 and 2

From: Volumetric magnetic resonance-guided high-intensity focused ultrasound ablation of uterine fibroids through abdominal scars: the impact of a scar patch on therapeutic efficacy and adverse effects

Treatment outcome

All patients

Group 1

Group 2

P value

Patients

63

17

46

 

 Fibroid volumea

  Baseline

171.7 ± 149.3 (6.0–794.0)

179.4 ± 176.1 (37.0–794.0)

168.9 ± 140.2 (6.0–637.0)

0.806

  6 months

92.4 ± 93.4 (4.0–578.0)

87.8 ± 68.6 (11.0–295.0)

94.1 ± 101.6 (4.0–578.0)

0.813

  Reduction ratio (6 months)

0.44 ± 0.22 (−0.21–0.84)

0.45 ± 0.27 (−0.03–0.80)

0.43 ± 0.21 (−0.21–0.84)

0.747

 Symptom severity scoreb

  Baseline

53.5 ± 16.5 (21.9–93.8)

55.0 ± 15.9 (31.2–87.5)

53.0 ± 16.5 (21.9–93.8)

0.672

  6 months

13.0 ± 19.8 (0.0–100.0)

16.5 ± 21.9 (0.0–62.5)

11.7 ± 19.0 (0.0–100.0)

0.391

  Improvement ratio (6 months)

0.77 ± 0.31 (−0.2–1.0)

0.7 ± 0.39 (−0.2–1.0)

0.79 ± 0.28 (−0.07–1.0)

0.055

  1. Values in parentheses represent ranges
  2. aLargest treated fibroid only
  3. bTransformed symptom severe score (SSS) can range from 0 to 100